Modipafant - 60 Degrees Pharmaceuticals Australia
Alternative Names: 60P 002; UK 80067Latest Information Update: 28 Mar 2021
At a glance
- Originator Pfizer
- Developer 60 Degrees Pharmaceuticals Australia; Pfizer
- Class Antiasthmatics; Antivirals; Dihydropyridines; Imidazoles; Small molecules
- Mechanism of Action Calcium channel antagonists; Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dengue
- Discontinued Asthma
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for phase-I development in Dengue in USA
- 06 Mar 2019 Modipafant is still in phase I trials for Dengue in USA (60 degrees pharmaceuticals pipeline, March 2019)
- 28 Oct 2018 No recent reports of development identified for phase-I development in Dengue in USA